NSTK · 01.2026Independent supplement reference
NutriStack
Edition 1.0Updated July 13, 2026

Brimonidine

Prescription ·Exploratory record · not publication-reviewed ·Updated July 13, 2026

Brimonidine is a selective alpha-2 adrenergic agonist used topically to reduce intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension. It lowers IOP by 15-20% through dual mechanisms: reducing aqueous humor production and increasing uveoscleral outflow. It is commonly used as second-line therapy or adjunctive to prostaglandin analogs, and is available in fixed combination with timolol (Combigan). A lower concentration formulation (Alphagan P 0.1%) with purite preservative has improved tolerability.

Evidence tier
Strong
Indexed sources
10 2000–2025
Interactions
0
Category
Prescription
Read the sources → Compare profiles
Publication status

Exploratory record, not a reviewed medical publication.

See the editorial and medical-review policies for the publication gate.

This generated database record has not completed a claim-level review by a qualified human medical reviewer. Bibliography links and evidence labels are not approval. The page remains available for reference and is excluded from search indexing.

In short

What the research says.

A quick, data-only summary. The full evidence, dosing, and sources are below.

Brimonidine is a selective alpha-2 adrenergic agonist used topically to reduce intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension. NutriStack rates the supporting evidence as strong. Common adult dosing is One drop of 0.1-0.2% solution in affected eye(s) three times daily, approximately 8 hours apart (as prescribed by your physician), though a prescriber sets the actual dose. This profile indexes 10 sources.

What it's good for
  • Dual mechanism: reduces aqueous production and increases uveoscleral outflow
  • Potential retinal neuroprotective properties
  • No significant effect on pupil size at standard doses
  • Available in fixed-combination with timolol for convenience4,5
What to watch for
  • Ocular allergy/allergic conjunctivitis (up to 25%, most common reason for discontinuation)
  • Dry mouth
  • Ocular hyperemia
  • Known hypersensitivity to brimonidine or any component1,2
  • Neonates and infants under 2 years of age (risk of severe CNS depression, apnea, hypotension, hypothermia)

The bottom line

Evidence rating strong. Most-documented uses: dual mechanism: reduces aqueous production and increases uveoscleral outflow, potential retinal neuroprotective properties, no significant effect on pupil size at standard doses. 10 sources indexed (2000–2025), with 0 interaction records on file.

The science

How it works, mechanistically.

Core mechanism

Selectively activates alpha-2 adrenergic receptors in the ciliary body, which reduces aqueous humor production via decreased cyclic AMP. Simultaneously increases uveoscleral outflow, providing a dual mechanism for IOP reduction. Also has potential neuroprotective properties for retinal ganglion cells by reducing apoptosis and increasing expression of brain-derived neurotrophic factor (BDNF), though clinical significance is under investigation.

Class
Alpha-2 Agonist / Ophthalmologic
Dosing

Dosing & protocol.

Common range
One drop of 0.1-0.2% solution in affected eye(s) three times daily, approximately 8 hours apart (as prescribed by your physician)
Recommended form
Ophthalmic solution; Alphagan P 0.1% (with purite preservative) preferred over 0.2% (with BAK) for better tolerability

Topical ophthalmic application; some systemic absorption occurs. Space at least 5 minutes between instillation of different eye drops. Can cause systemic alpha-2 agonist effects, especially in small children (contraindicated in infants and neonates).5

Safety

Full safety detail.

Side effects

  • Ocular allergy/allergic conjunctivitis (up to 25%, most common reason for discontinuation)
  • Dry mouth
  • Ocular hyperemia
  • Burning and stinging
  • Fatigue and drowsiness (systemic)
  • Foreign body sensation
  • Follicular conjunctivitis

Contraindications

  • Known hypersensitivity to brimonidine or any component1,2
  • Neonates and infants under 2 years of age (risk of severe CNS depression, apnea, hypotension, hypothermia)
  • Concurrent use with MAO inhibitors
  • Severe cardiovascular disease
  • Children ages 2-7 (use with caution; higher risk of CNS depression)
Sources

Sources, by evidence tier.

Numbered references. Citations throughout the page link here.

Meta-analyses & systematic reviews

3

Randomized controlled trials

3

Reference material

4
FAQ

Common questions.

Quick answers about Brimonidine, drawn from the data on this page.

What is Brimonidine?

Brimonidine is a selective alpha-2 adrenergic agonist used topically to reduce intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension. It lowers IOP by 15-20% through dual mechanisms: reducing aqueous humor production and increasing uveoscleral outflow. It is commonly used as second-line therapy or adjunctive to prostaglandin analogs, and is available in fixed combination with timolol (Combigan). A lower concentration formulation (Alphagan P 0.1%) with purite preservative has improved tolerability.

What is Brimonidine used for?

Commonly cited benefits of Brimonidine include: Dual mechanism: reduces aqueous production and increases uveoscleral outflow; Potential retinal neuroprotective properties; No significant effect on pupil size at standard doses; Available in fixed-combination with timolol for convenience. NutriStack rates the overall evidence as strong.

What is a typical dose of Brimonidine?

A typical adult dose of Brimonidine is One drop of 0.1-0.2% solution in affected eye(s) three times daily, approximately 8 hours apart (as prescribed by your physician). The commonly recommended form is Ophthalmic solution; Alphagan P 0.1% (with purite preservative) preferred over 0.2% (with BAK) for better tolerability. These are general ranges, not personalized advice; confirm the right dose with a clinician.

What are the side effects of Brimonidine?

Reported side effects include ocular allergy/allergic conjunctivitis (up to 25%, most common reason for discontinuation), dry mouth, ocular hyperemia, burning and stinging, fatigue and drowsiness (systemic), foreign body sensation. This is educational information; check with a healthcare professional before use.

How strong is the evidence for Brimonidine?

NutriStack rates this as Strong, meaning multiple high-quality meta-analyses or systematic reviews converge on the same finding. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.

Use this with your stack

Brimonidine in NutriStack.

Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.

Download on the App Store → Read the methodology

NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.